<DOC>
	<DOC>NCT00777582</DOC>
	<brief_summary>The purpose of this phase I randomised cross over study is to determine and compare the bioavailability of two different oral formulations of AZD2281 in advanced solid tumour cancer patients</brief_summary>
	<brief_title>Phase I Comparative Bioavailability Study</brief_title>
	<detailed_description />
	<mesh_term>Olaparib</mesh_term>
	<criteria>Histologically confirmed malignant advanced solid tumour, which is refractory to standard therapies (except Group 8 patients who must not be platinum refractory) or for which no suitable effective standard therapy exists Patients must have adequate organ and bone marrow function measured within 7 days prior to administration of study treatment Female patients must have evidence of nonchild bearing status: negative urine or serum pregnancy test within 7 days of study treatment for women of child bearing, or postmenopausal status Patients receiving chemotherapy, radiotherapy (except for palliative reasons) or any other anticancer therapy within 4 weeks of the last dose prior to study entry. Patients may continue the use of biphosphonates for bone metastases and corticosteroids Patients with symptomatic uncontrolled brain metastases Major surgery within 2 weeks of starting study and patients must have recovered from any effects of any major surgery Patients who are platinum refractory (Group 8 only) Patients with myelodysplastic syndrome/acute myeloid leukaemia (Group 8 only).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Poly (ADP ribose) polymerases</keyword>
	<keyword>Homologous Recombination Deficiency (HRD)</keyword>
	<keyword>Advanced solid tumours</keyword>
</DOC>